724.87
price down icon1.00%   -7.33
after-market  After Hours:  726.51  1.64   +0.23%
loading
Lilly(Eli) & Co stock is currently priced at $724.87, with a 24-hour trading volume of 2.56M. It has seen a -1.00% decreased in the last 24 hours and a -6.24% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $737.9 pivot point. If it approaches the $723.1 support level, significant changes may occur.
Previous Close:
$732.20
Open:
$725
24h Volume:
2.56M
Market Cap:
$689.18B
Revenue:
$34.12B
Net Income/Loss:
$5.24B
P/E Ratio:
133.76
EPS:
5.4193
Net Cash Flow:
$-3.15B
1W Performance:
-2.83%
1M Performance:
-6.24%
6M Performance:
+23.60%
1Y Performance:
+88.36%
1D Range:
Value
$718.30
$727.99
52W Range:
Value
$370.68
$800.78

Lilly(Eli) & Co Stock (LLY) Company Profile

Name
Name
Lilly(Eli) & Co
Name
Phone
317-276-2000
Name
Address
Lilly Corporate Center, Indianapolis, IN
Name
Employee
38,585
Name
Twitter
@LillyPad
Name
Next Earnings Date
2024-05-06
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Lilly(Eli) & Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly(Eli) & Co Stock (LLY) Financials Data

Lilly(Eli) & Co (LLY) Revenue 2024

LLY reported a revenue (TTM) of $34.12 billion for the quarter ending December 31, 2023, a +19.56% rise year-over-year.
loading

Lilly(Eli) & Co (LLY) Net Income 2024

LLY net income (TTM) was $5.24 billion for the quarter ending December 31, 2023, a -16.08% decrease year-over-year.
loading

Lilly(Eli) & Co (LLY) Cash Flow 2024

LLY recorded a free cash flow (TTM) of -$3.15 billion for the quarter ending December 31, 2023, a -168.52% decrease year-over-year.
loading

Lilly(Eli) & Co (LLY) Earnings per Share 2024

LLY earnings per share (TTM) was $5.6864 for the quarter ending December 31, 2023, a -16.37% decline year-over-year.
loading

Lilly(Eli) & Co Stock (LLY) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Zakrowski Donald A
SVP, Finance, & CAO
Mar 11 '24
Sale
753.60
750
565,200
7,880
LILLY ENDOWMENT INC
10% Owner
Feb 16 '24
Sale
780.99
169,684
132,521,930
98,898,810
LILLY ENDOWMENT INC
10% Owner
Feb 15 '24
Sale
760.46
50,316
38,263,417
99,068,494
LILLY ENDOWMENT INC
10% Owner
Feb 09 '24
Sale
740.60
206,257
152,753,428
99,118,810
LILLY ENDOWMENT INC
10% Owner
Feb 08 '24
Sale
740.06
8,743
6,470,336
99,325,067
Van Naarden Jacob
EVP & Pres., Loxo@Lilly
Feb 01 '24
Option Exercise
0.00
3,618
0
15,463
White Anne E.
EVP & Pres, Lilly Neuroscience
Feb 01 '24
Option Exercise
0.00
4,124
0
62,050
Skovronsky Daniel
EVP, CSO & Pres. LRL & LLY Imm
Feb 01 '24
Option Exercise
0.00
9,941
0
115,262
Norton Johna
EVP, Global Quality
Feb 01 '24
Option Exercise
0.00
1,268
0
31,382
Hakim Anat
EVP, GC & Secretary
Feb 01 '24
Option Exercise
0.00
4,442
0
26,631
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; and Dicerna Pharmaceuticals, Inc., as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
drug_manufacturers_general JNJ
$146.82
price down icon 1.15%
drug_manufacturers_general MRK
$130.72
price up icon 2.93%
$167.29
price down icon 0.30%
drug_manufacturers_general NVS
$99.06
price up icon 0.72%
$269.38
price down icon 1.33%
Cap:     |  Volume (24h):